Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy
The number of elderly head-and-neck squamous cell carcinoma (HNSCC) patients is increasing;
however, the evidence regarding the ideal treatment for this often vulnerable and frail
patient cohort is limited. Although the benefit of concomitant chemotherapy has been r...
Age: 65 years - 66+
Gender: All
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
This phase II trial studies the effect of pembrolizumab in combination with radiation therapy
or pembrolizumab alone compared to the usual approach (chemotherapy plus radiation therapy)
after surgery in treating patients with head and neck squamous cell carcinoma th...
Age: 18 - 79 years
Gender: All
First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics,
pharmaco-dynamics and preliminary anti-tumor activity of DRP-104 (sirpiglenastat)
administered via intravenous infusion or via subcutaneous injection as a single agent and in
...
Age: 18 years - 66+
Gender: All
Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma
The purpose of this research study is to investigate a shorter radiation treatment schedule
for head and neck cancers in patients 70 years of age and older.
Standard radiation treatment for head and neck patients normally requires that the patient
travel to the ...
Age: 70 years - 66+
Gender: All
A Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies
ATRC-101-A01 is a Phase 1b, open-label dose escalation trial of ATRC-101, an engineered fully
human immunoglobulin G, subclass 1 (IgG1) antibody derived from a naturally occurring human
antibody. The safety, tolerability, PK, and biological activity of ATRC-101 will...
Age: 18 years - 66+
Gender: All
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC
The primary objective of the study is to evaluate the clinical activity of neoadjuvant
cemiplimab therapy in patients with resectable Non-small cell lung cancer (NSCLC),
Hepatocellular carcinoma (HCC), and Head and neck squamous cell carcinoma (HNSCC) lesions, as
...
Age: 18 years - 66+
Gender: All
Vaccination With Flt3L, Radiation, and Poly-ICLC
This is a combination of 4 therapies, three of which are used to treat a single "target site"
of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into
the blood stream (intravenous or "IV").
1. Radiation: The target site --lymph nod...
Age: 18 years - 66+
Gender: All
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a
humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult
subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, ...
Age: 18 years - 66+
Gender: All
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
This phase II/III trial studies how well radiation therapy works when given together with
cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with
high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squ...
Age: 18 years - 66+
Gender: All